Corvus Pharmaceuticals (CRVS) Other Accumulated Expenses (2022 - 2025)
Historic Other Accumulated Expenses for Corvus Pharmaceuticals (CRVS) over the last 4 years, with Q3 2025 value amounting to $566000.0.
- Corvus Pharmaceuticals' Other Accumulated Expenses rose 4079.6% to $566000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $566000.0, marking a year-over-year increase of 4079.6%. This contributed to the annual value of $289000.0 for FY2024, which is 1795.92% up from last year.
- According to the latest figures from Q3 2025, Corvus Pharmaceuticals' Other Accumulated Expenses is $566000.0, which was up 4079.6% from $346000.0 recorded in Q2 2025.
- In the past 5 years, Corvus Pharmaceuticals' Other Accumulated Expenses registered a high of $566000.0 during Q3 2025, and its lowest value of $131000.0 during Q2 2022.
- Moreover, its 4-year median value for Other Accumulated Expenses was $245000.0 (2023), whereas its average is $266666.7.
- Per our database at Business Quant, Corvus Pharmaceuticals' Other Accumulated Expenses skyrocketed by 8578.43% in 2023 and then tumbled by 5277.04% in 2024.
- Corvus Pharmaceuticals' Other Accumulated Expenses (Quarter) stood at $158000.0 in 2022, then soared by 55.06% to $245000.0 in 2023, then rose by 17.96% to $289000.0 in 2024, then soared by 95.85% to $566000.0 in 2025.
- Its Other Accumulated Expenses was $566000.0 in Q3 2025, compared to $346000.0 in Q2 2025 and $296000.0 in Q1 2025.